Recruiting
Phase 1

NNC4004-0002

Sponsor:

Novo Nordisk A/S

Code:

NCT06859073

Conditions

Healthy Volunteers

Hyperuricemia

Eligibility Criteria

Sex: All

Age: 35 - 70+

Healthy Volunteers: Accepted

Interventions

NNC4004-0002

Placebo

Study Details

Brief summary:

This study will evaluate an investigational drug called NNC4004-0002. "Investigational" means NNC4004-0002 has not been approved for sale/ for clinical use or for the use described in this study/ by any regulatory authority. Its use in this study is experimental. This will be the first time that NNC4004-0002 will be given to human. This study will be testing the ability of the study medicine to lower serum uric acid. The main aim of this study will be to see if the new study medicine is safe and tolerated by the body after a single dose of study medicine in adults with asymptomatic hyperuricemia. Participants will either get NNC4004-0002 (the study medicine), or saline. Which treatment the participant get will be decided by chance. The participant will get the medicine as an injection under their skin. Depending on the dose they will receive, participant may need more than one injection. The study will last for about 19 months in total. The participant will take part in the study for about 7 months. Participant will have approximately 14 visits to the clinic and one of them will be a 4 night in-house stay.

Conditions

Healthy Volunteers

Hyperuricemia

Study ID

NCT06859073

Start date

Nov 13, 2024

Status verified date

Sep, 2025

Completion date

Jun 1, 2026

Anticipated

Primary completion date

Jun 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 35 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Males or females 35 to 75 years of age at the time of signing the informed consent form (ICF).
  • Considered to be generally healthy based on medical history, physical examination, and the re-sults of vital signs, electrocardiogram, and clinical laboratory tests performed during the screening visit, as judged by the investigator.
  • Body mass index (BMI) 20 to 35 kilogram per meter square (kg/m2) (both inclusive) at screening.
  • Serum uric acid levels greater than or equal to (≥) 6.8 miligram per decileter (mg/dL) to less than or equal (≤) 12 mg/dL on 2 consecutive screening samples (the first at the screening visit \[V1\], and the second taken at V2 \[day -1\]; samples at least 7 days apart).

Exclusion Criteria:

  • Female who is pregnant, breastfeeding, or intends to become pregnant or is of childbearing po-tential and not using an adequate contraceptive method.
  • Male of reproductive age who, or whose female partner(s), is not using an adequate contraceptive method.
  • Present or prior history of gout, or present or prior use of serum Uric acid (sUA) lowering medication.
  • Serious cardiovascular or hepatic disease, current or past malignancies, or chronic debilitating neurologic, gastrointestinal, or inflammatory diseases.
  • History or current diagnosis of chronic history kidney disease.
  • Screening alanine transaminase (ALT) or aspartate aminotransferase (AST) values greater than (>) 2 multiply by (×) upper limit normal (ULN) or total bilirubin >1.5× ULN.

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: NNC4004-0002

Participants will receive a single dose of NNC4004-0002 injected subcutaneously. Trial will include up to 6 ascending single-dose cohorts.

placebo comparator: Placebo

Participants in each cohort will receive placebo matched to NNC4004-0002 injected subcutaneously.

Interventions

NNC4004-0002

NNC4004-0002 will be given as a single ascending dose via subcutaneous route.

Placebo

Placebo matched to NNC4004-0002 will be given via subcutaneous route.

Primary outcome measure

  • Number of Treatment-emergent adverse event (TEAEs) [ Time Frame: From dosing (day 1) until end of study (approximately 28 weeks) ]

Central Contacts and Locations

Central contacts

Novo Nordisk

(+1) 866-867-7178clinicaltrials@novonordisk.com

Locations

PAREXEL Intl - EPCU-Baltimore

Recruiting

Baltimore, Maryland, United States, 21225

More Information

Sponsor

Novo Nordisk A/S

Last update posted

Sep 24, 2025

Last verified

Sep, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Novo Nordisk A/S on 2025-09-24.